A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
Kian JalaleddiniRobert A BermelBari TalenteDavid WeinsteinFerhan QureshiMaital RasmussenSreeranjani MenonMiyuru AmarapalaKesshi JordanAti GhoreyshiShannon McCurdyMike EdgeworthPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
While there are increased clinical and cost benefits as more eligible patients attempt discontinuation, the risk of relapses can increase. Timely disease monitoring is required to manage safe DMT discontinuation.
Keyphrases
- disease activity
- multiple sclerosis
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- ejection fraction
- newly diagnosed
- healthcare
- public health
- ankylosing spondylitis
- chronic kidney disease
- prognostic factors
- mental health
- juvenile idiopathic arthritis
- peritoneal dialysis
- white matter
- climate change